

1 **Appendix - Biphasic response as a mechanism against mutant takeover in tissue**  
2 **homeostasis circuits**


3 **Table of Contents**

4 **APPENDIX - BIPHASIC RESPONSE AS A MECHANISM AGAINST MUTANT**  
5 **TAKEOVER IN TISSUE HOMEOSTASIS CIRCUITS ..... 1**  
6 *Appendix Section S1. Modeling the growth rate of cells in tissue homeostasis circuits. .... 2*  
7 *Appendix Section S2. Modeling input delay in feedback homeostasis circuits. .... 4*  
8 *Appendix Section S3. Simulation of glucose dynamics and the induction of a glucokinase mutant.*  
9 *..... 6*  
10 *Appendix Section S4. Derivation of the evolutionary stability of a circuit with biphasic control.*  
11 *..... 10*  
12 *Appendix Section S5. Evolutionary stability of circuits that consist of multiple compartments.. 14*  
13 **REFERENCES..... 17**  
14

15

16

17 Appendix Section S1. Modeling the growth rate of cells in tissue homeostasis circuits.



18

19 **Appendix Figure S1.** Adding carrying capacity  $K$  to the circuits preserves the conclusions of the study.

20 Simulation of an event where a strong activating mutant arises either in a circuit with monophasic control (A-C)

21 or biphasic control (D-F) with logistic growth with a carrying capacity  $K$ . The arrows mark the times when a

22 mutant with a strong activation of the sensing of  $y$  arises. As was the case for exponential growth, also under

23 logistic growth the monophasic circuit is susceptible to mutant invasion whereas the biphasic circuit is not.

24

25 In this section, we ask whether changing exponential growth to logistic growth in the

26 circuits affects the conclusions. In the main text, we analyzed circuits where cells  $Z$  adjust

27 their own growth rate as a function of a signal  $y$ , which, in turn, is affected by the size of the

28 tissue. The signal  $y$  affects the growth rate of cells by affecting either their proliferation or

29 removal rate, so we can model the dynamics of  $Z$  using the following equation:

30 
$$\dot{Z} = Z \cdot (\lambda_+(y) - \lambda_-(y)) \quad [1]$$

31 Where  $\lambda_+$  is the  $y$ -dependent proliferation rate of  $Z$  and  $\lambda_-$  is the  $y$ -dependent removal rate of  
32  $Z$ . As discussed the main text, the feedback on  $Z$  through  $y$  can robustly maintain tissue size,  
33 but is susceptible to the invasion of mis-sensing mutants.


34 The growth rate of  $Z$  can be either logistic or exponential. Exponential growth means  
35 that the production rate  $\lambda_+$  does not depend on  $Z$  (for example  $\lambda_+=y$ ), and is relevant when the  
36 cells are far from carrying capacity. When the cells are closer to carrying capacity, however,  
37 a logistic model more appropriately models the dynamics of  $Z$ :

$$38 \quad \dot{Z} = Z \cdot \left( \lambda_+(y) \cdot \left(1 - \frac{Z}{K}\right) - \lambda_-(y) \right) \quad [1]$$

39 In which proliferation rate drops to zero as cells approach the carrying capacity  $K$ .

40 The conclusions of the manuscript hold both when the growth of the cells is logistic  
41 or exponential (Appendix Figure S1): the biphasic circuit is resistant whereas the monophasic  
42 circuit is not.

43



45

46 **Appendix Figure S2.** Simulation of an event where a strong activating mutant arises either in a circuit with  
 47 monophasic control (A-C) or biphasic control (D-F). The arrows mark the times when a mutant with a strong  
 48 activation of the sensing of  $y$  arises. The circuits are similar to the circuits depicted in Fig. 1B and Fig. 1F,  
 49 except that  $Z$  acts on  $y$  with delay modeled by an intermediate variable  $r$  with delay parameter  $\tau$ . As was the case  
 50 without  $r$ , also here the monophasic circuit is susceptible to mutant invasion whereas the biphasic circuit is not.

51

52 In the main text, we analyzed circuits where cells  $Z$  adjust their own growth rate as a  
 53 function of a signal  $y$ , which, in turn, is affected by the size of the tissue. Here, we consider  
 54 the case where  $y$  affects  $Z$  with a delay. Delays occur in endocrine circuits, where the level of  
 55 the regulated variable (e.g. blood glucose) is controlled with a delay relative to its regulating  
 56 hormone (insulin).

57 In the examples of Figure 1 we used the following equations to model the mutant  
 58 resistance of the circuits in Fig. 1BF:

59 
$$\dot{y} = \mu \cdot (M - (Z + Z_{mut})y) \quad [1]$$

60 
$$\dot{Z} = Z \cdot (\lambda_+(y) - \lambda_-(y)) \quad [2]$$

61 We tested whether adding a delay to this system affects the resistance of monophasic or  
62 biphasic circuits to sensing mutants. To do so, we modify the equations so they include an  
63 intermediate variable  $r$  with a typical timescale  $\tau$ :

64 
$$\dot{r} = \tau \cdot (Z + Z_{mut} - r) \quad [1]$$

65 
$$\dot{y} = \mu \cdot (M - ry) \quad [2]$$


66 
$$\dot{Z} = Z \cdot (\lambda_+(y) - \lambda_-(y)) \quad [3]$$

67 The parameter  $\tau$  represents the delay of the system. We tested the effect of 3 different  
68 values of  $\tau$  on the resistance to mutants (Appendix Figure S2) -  $\tau=0.01$  (slow),  $\tau=1$   
69 (intermediate) and  $\tau=100$  (fast). For all these values of  $\tau$ , an activating mutant invades the  
70 monophasic circuit but does not invade the biphasic circuit.

71

72

73 Appendix Section S3. Simulation of glucose dynamics and the induction of a glucokinase  
 74 mutant.



75  
 76 **Appendix Figure S3.** Simulation of a Tamoxifen-induced conditional knock-in of a 6-fold activating mutant on  
 77 GCK in beta cells. Dynamics were simulated using explicit equations for insulin and glucose dynamics.

78

79 Blood glucose levels are regulated by the hormone insulin which secreted by  
 80 pancreatic beta cells. The dynamics of glucose as a function of insulin can be described by  
 81 the following minimal model (Bergman, 1989):

$$82 \quad \dot{G} = u_0 + u(t) - (C + S_i I) \cdot G \quad [1]$$

83 where  $I$  is plasma insulin concentration,  $u_0$  is endogenous production of glucose,  $u(t)$  is  
 84 meal intake,  $C$  is glucose removal rate at zero insulin and  $S_i$  is insulin sensitivity. Secretion of  
 85 insulin is proportional to beta cell functional mass  $\beta$  and is modeled by the equation:

$$86 \quad \dot{I} = p\beta \cdot \frac{G^{1.7}}{\alpha^{1.7} + G^{1.7}} - \gamma I \quad [2]$$

87 Where  $\rho(G)$  is a monotonically increasing function of  $G$ ,  $\gamma$  is the insulin removal rate and  $p$  is  
 88 the insulin secretion per cell. Last, there is also a slow feedback where glucose controls the  
 89 dynamics of beta cell proliferation and removal (Karin et al., 2016):

$$90 \quad \dot{\beta} = \beta(\lambda_+(G) - \lambda_-(G)) = \beta \cdot \lambda(G) \quad [3]$$

91 The function  $h(G)$  has a stable fixed point at  $G = 5mM$ . This slow feedback provides the  
 92 system with robustness to variation in  $S_i, p$  since at steady state the dynamics of glucose to  
 93 any input does not depend on these parameters (e.g. the system shows dynamical  
 94 compensation (Karin et al., 2016)).

95 The function  $h(G)$  also has an unstable fixed point at some  $G \gg 5$ , which results from  
 96 glucose-dependant toxicity (glucotoxicity). This unstable fixed point can cause paradoxical  
 97 beta cell death after an increase in glucose levels, which, in a self-reinforcing manner, further  
 98 increases glucose levels. This process may underlie type 2 diabetes (De Gaetano et al., 2008;  
 99 Ha et al., 2016; Karin et al., 2016; Topp et al., 2000). For our simulation, which is intended to  
 100 represent young mice, we set this unstable fixed point to  $G=13.5\text{mM}$  (Efanova et al., 1998;  
 101 Maedler et al., 2006). The exact level of the unstable fixed point is not important for our  
 102 conclusions, since a lower or higher unstable fixed point will work as well (as long as it is  
 103 significantly smaller than  $G=30\text{mM}$ ). We used the following function to model glucose  
 104 dependent removal of beta cells:

$$\lambda_-(G) = \mu_- \cdot \left( \frac{1}{1 + \left(\frac{G}{4}\right)^8} + \frac{1}{1 + \left(\frac{15}{G}\right)^6} \right)$$

105 This death rate is similar to the glucose dependent death curve that is observed by Efanova et  
 106 al (Efanova et al., 1998). Glucose dependent proliferation rate was modelled as in Karin et al  
 107 (Karin et al., 2016):

$$\lambda_+(G) = \mu_+ \cdot \frac{1}{1 + \left(\frac{8.4}{G}\right)^{1.7}}$$

108 The values of  $\mu_+, \mu_-$  determine the turnover of beta cell functional mass and were set as:

$$\mu_+ = 0.1 \cdot \text{day}^{-1}$$

$$\mu_- = 0.2 \cdot \text{day}^{-1}$$

109 These values correspond to a  $\sim 3\%$  turnover of beta cell functional mass per day. All other  
 110 parameters of the  $\beta IG$  model were set as follows (Karin et al., 2016):

Parameter	Value	Units
$u_0$	$\frac{1}{30}$	$\text{mM min}^{-1}$

$C$	$10^{-3}$	$\text{min}^{-1}$
$S_i$	$5 \cdot 10^{-4}$	$\text{ml } \mu\text{U}^{-1} \text{min}^{-1}$
$p$	0.03	$\text{mg}^{-1} \mu\text{U ml}^{-1} \text{min}^{-1}$
$\alpha$	8.4	mM
$\gamma$	0.3	$\text{min}^{-1}$

111

112

113

114

115

116

A beta-cell mutant with  $k$ -fold activation on the sensing of glucose has both a  $k$ -fold scaling of insulin secretion ( $\rho(G) \rightarrow \rho(kG)$ ) and a  $k$ -fold scaling in its response in terms of growth rate ( $\lambda(G) \rightarrow \lambda(kG)$ ). Therefore, to simulate the Y214C mutant (that has a 6-fold activation in glucose sensing) we simply replaced the secretion and growth functions accordingly, using  $k = 6$ . The combined equation for insulin secretion is the following:

$$\dot{I} = p\beta \cdot \frac{G^{1.7}}{\alpha^{1.7} + G^{1.7}} + p\beta_{mut} \cdot \frac{(kG)^{1.7}}{\alpha^{1.7} + (kG)^{1.7}} - \gamma I$$

117

118

Finally, in the experiment the Cre-mediated transgene was induced by tamoxifen. We simulated tamoxifen as converting normal beta cells to mutated beta cells:

$$\dot{\beta} = \beta(\lambda_+(G) - \lambda_-(G) - T)$$

$$\dot{\beta}_{mut} = \beta_{mut}(\lambda_+(kG) - \lambda_-(kG)) + \beta T$$

119

120

with  $T$  representing the concentration of tamoxifen in the blood. The dynamics of tamoxifen were simulated as exponential degradation with a half-life of 16 hours (Robinson et al., 1991)

121

$$\dot{T} = \frac{-\log(2)}{16 \cdot 60} T.$$

122

The initial values used for the simulation:

Parameter	Value	Units
$T$	0.27	$\text{day}^{-1}$
$G$	4.966667	mM



$I$	11.42	$\mu\text{U ml}^{-1}$
$\beta$	400	mg
$\beta_{mut}$	0	mg

123

124

125

126

127

128

129

130

131

We simulated the dynamics of the system both by (i) assuming a quasi-steady-state for beta cell mass and solving equations [1],[2] to compute glucose levels, and (ii) explicitly modeling the dynamics of glucose and insulin using equations [1], [2], which adds a delay to the circuit. The model was simulated for  $t = 40 \cdot 24 \cdot 60$  minutes. The results from (i) are provided in Fig. 1 in the main text and the results from (ii) are provided here as a supplementary figure (Appendix Figure S3). Because beta cell mass changes much slower than glucose, both methods yield highly similar results.

132 Appendix Section S4. Derivation of the evolutionary stability of a circuit with biphasic  
133 control.

134 Here we derive a formula that approximates the evolutionary stability of a circuit with  
135 biphasic control. First, we provide a definition for the evolutionary stability of a circuit.

136 **Definition 1.1.** The *strategy*  $S$  of a cell is defined as its (daily) death and proliferation  
137 probabilities for all inputs  $c$ :  $S=\{d(y),p(y)\}$ . A strategy  $S'=\{d'(y),p'(y)\}$  is denoted as an  
138 alternative strategy to  $S$  if there are inputs  $y$  for which either  $p'(y) \neq p(y)$ ,  $d'(y) \neq d(y)$ .  
139 The strategy that is adopted by a population of cells, as well as the output response of these  
140 cells to the input  $y$ , determines the function of the homeostatic circuit.

141 **Definition 1.2.** The *evolutionary stability* of a strategy  $S$  is defined as the probability that  
142 given that the entire population of cells adopts  $S$ , it will not be invaded by an alternative  
143 strategy  $S'$  by time  $t$ .

144 If the entire population adopts a strategy  $S$  then for an alternative strategy  $S'$  to invade  
145 the circuit, it must first arise via mutation. The probability that  $S'$  will arise via mutation from  
146 a cell with a strategy  $S$  is the probability of a transition  $S \rightarrow S'$ , which we denote it as  $\mu_S(S')$ .  
147 After a mutant arises, it must then invade the population. We denote the probability that such  
148 a mutant will invade the population as  $\rho_S(S')$ .

149 For a circuit of  $N$  interacting cells with a turnover rate  $\tau^{-1}$ , the probability that no  
150 invading alternative strategy will arise by time  $t$  is:

$$\zeta_S(t) = \left( \prod_{S'} (1 - \mu_S(S')\rho_S(S')) \right)^{N\tau^{-1}t} \quad [1]$$

151 We estimate the invasion probability  $\rho_S(S')$  by modeling the evolutionary dynamics of  
152 the circuit using a Moran-like stochastic process with variable death and proliferation  
153 probabilities.

154 **Definition 1.2.** Consider a population of cells with strategies  $\{S_1, \dots, S_N\}$  with corresponding  
 155 death and proliferation probabilities  $S_i=\{d_i, p_i\}$ . The *Extended Moran Process (EMP)* is  
 156 defined as follows: in each round, one strategy replicates and one strategy is eliminated. The  
 157 probability for elimination for strategy  $S_i$  is  $\frac{d_i}{\sum_{j=0}^N d_j}$  and the probability for replication is  
 158  $\frac{p_i}{\sum_{j=0}^N p_j}$ . The relative fitness of a strategy is defined as  $r = \frac{p_i}{d_i}$ .

159 **Lemma 1.1.** The probability that a strategy  $S_i$  will take over the population in the Extended  
 160 Moran Process is:  $\rho_{S_i} = \frac{1 - \frac{1}{r}}{1 - \frac{1}{r^N}}$ .

161 **Proof.** The proof is the same as the proof for the fixation probability of the standard Moran  
 162 Process (Nowak, 2006), by simply setting the death probability as non-constant.

163 **Theorem 1.1.** The probability that an alternative strategy  $S'=\{d'(y), p'(y)\}$  invades a  
 164 homeostatic circuit is:

$$\rho_S(S') \approx \frac{1 - \frac{1}{r}}{1 - \frac{1}{r^N}} \quad [2]$$

165 where  $r = \frac{p'(y_{ST})}{d'(y_{ST})}$  with  $y=y_{ST}$  being the homeostatic set-point, and  $N$  being the number of cells  
 166 in the original population at steady-state. For a  $N>10$  and  $r>1$  this is approximately  
 167  $\rho_S(S'|r > 1) \approx 1 - \frac{1}{r}$ , while for  $r<1$  the invasion probability approaches zero:  $\rho_S(S'|r <$   
 168  $1) \approx 0$ .

169 **Proof.** This result follows directly from *Lemma 1.1* when we model the evolutionary  
 170 dynamics of the population using EMP. Note that the assumptions of EMP are not met  
 171 precisely – if cells with  $S'$  proliferate more rapidly than cells with  $S$  die, then the population  
 172 size exceeds  $N$  and  $y \neq y_{ST}$  before  $S'$  invades the circuit. Nevertheless, for a mutant with a  
 173 fitness advantage, the highest probability of elimination occurs when its frequency is

174 relatively small, and thus when the overall number of cells is approximately  $N$  and the  
 175  $y \approx y_{ST}$ .

176 Next we analyze the transition probability  $\mu_S(S')$  for some alternative strategy  $S'$ . We  
 177 assume that the transition  $S \rightarrow S'$  results from random mutations in enzymes. Consider such  
 178 an enzyme with an output that is described by a Hill equation:  $f(x) = v_m \frac{1}{1+(Kx^{-1})^n}$ . A  
 179 mutation that changes  $K \rightarrow K'$  results in a scaled output response:

$$f'(x) = v_{max} \frac{1}{1+(K'x^{-1})^n} = v_{max} \frac{1}{1+(K \cdot (x^{-1}K^{-1}K'))^n} = f(x^{-1}K^{-1}K')$$

180 We define  $\chi = K^{-1}K'$ . In a circuit with biphasic control where the enzyme is upstream both  
 181 death and proliferation this mutation will result in an alternative strategy  $S'=\{d(\chi y),p(\chi y)\}$ .  
 182 Other mutations that change  $v_{max}$  or  $n$  may have an effect on input sensing that is not  
 183 necessarily scaling (the effect depends on the structure of the signaling network), but for the  
 184 simplicity of the analysis we approximate the effect of every mutation as if it scales the input.

185 Thus, every mutation that affects sensing corresponds to some scaling value  $\chi$ . The  
 186 scaling  $\chi$  can range from  $\chi = 0$  (locked off) to  $\chi = \infty$  (locked on) with  $\chi = 1$  being a neutral  
 187 mutation with respect to sensing. We define the probability density function  $P_S(\chi)$  over  
 188  $\chi \in [0, \infty]$  to approximate the probability that a mutant with a scaling  $\chi$  will arise by  
 189 mutation from a population with strategy  $S$ . The measure  $\mu_S(\chi)$  is defined to be equal to  
 190  $P_S(\chi)$  for all  $\chi \neq 1$  and  $\mu_S(1) = 0$ . In addition, for every scaling  $\chi$  we can infer the invasion  
 191 probability using [Theorem 1.1]:

$$r(\chi) = \frac{p(\chi y_{ST})}{d(\chi y_{ST})} \quad [3]$$

192 The evolutionary stability of the circuit can be inferred by integrating over all possible  
 193 values of  $\chi$ :


$$\zeta_S(t) = e^{N\tau^{-1}t \int_0^\infty \log(1-\mu_S(\chi)\rho_S(\chi))d\chi} \quad [4]$$

194 To further simplify the analysis we use a zero-order approximation of  $\mu_S(\chi) = \mu_0$   
 195 around  $\chi = 1$ , which is the relevant range where sensing mutants may have a fitness  
 196 advantage over wild-type cells. The value of  $\mu_0$  depends both on DNA replication fidelity and  
 197 on the number of mutations that affect  $\chi$ , which may be, for instance, the number of  
 198 mutations that affect the kinetics or expression level of a rate-limiting enzyme.

199 Let us now consider a circuit with biphasic control, an unstable fixed point  $y_{UST}$  and a  
 200 stable fixed point  $y_{ST}$ . The input range where proliferation exceeds death is  $y_{ST} \leq y \leq y_{UST}$   
 201 and we assume a step change in that range so  $\frac{p(y)}{d(y)} = \nu$  in that range. The population size is  
 202  $N > I\theta$  and we denote  $\delta = \frac{y_{UST}}{y_{ST}} - I$ . Thus, only for  $I < \chi < I + \delta$  is the invasion  
 203 probability  $\rho_S(\chi)$  non-negligible and is equal to  $\rho_S(\chi) = I - \frac{I}{\nu}$ . The evolutionary stability of  
 204 this circuit is thus:

$$\begin{aligned} \zeta_S(t) &= e^{N\tau^{-1}t \int_I^{I+\delta} \log\left(I - \mu_0\left(I - \frac{I}{\nu}\right)\right) d\chi} \approx e^{N\tau^{-1}t \int_I^{I+\delta} \mu_0\left(I - \frac{I}{\nu}\right) d\chi} \\ &= e^{N\tau^{-1}t \delta \mu_0\left(I - \frac{I}{\nu}\right)} \end{aligned}$$

205



207

208 **Appendix Figure S4.** Architectures of compartmentalizations for intercellular communication.

209

210 Tissues of multicellular organisms are often subdivided into compartments such as intestinal  
211 crypts or pancreatic islets (Jo et al., 2007; Michor et al., 2003; Mintz, 1971). The number of  
212 cells in each compartment is limited and cannot exceed a certain size, and thus they confine  
213 invading mutants. We now extend our analysis to the case where the cells in a circuit are  
214 subdivided into many compartments (Appendix Figure S4). In addition to the non-  
215 compartmentalized case (Appendix Figure S4A), there are two possible scenarios: either the  
216 cellular communication is local to each compartment (Appendix Figure S4B, e.g. paracrine  
217 signaling) or the communication is systemic, between compartments (Appendix Figure S4C,  
218 e.g. the control of metabolites by endocrine tissues).

219 *Local communication:* If each compartment is of similar size then each compartment has the  
220 same evolutionary stability  $\zeta$ . This value  $\zeta$  is the same as the expected fraction of  
221 compartments that have an invading mutant by time  $t$ .

222 *Systemic communication:* Consider now the case where the communication occurs across the  
223 entire population and the circuit has only one non-trivial stable fixed-point. If a mutant  
224 invades a compartment then the homeostatic set point for all the cells in that compartment is  
225 different from that of the rest of the population. Recall that in the non-compartmentalized

226 case the system can be at steady state only when all the cells of the population have the same  
227 strategy (that is, the same scaling  $\chi$ ). This is not the case when the population is subdivided  
228 into compartments. The reason for this is that while the cells in the invading compartment  
229 may have a positive growth rate when the system is at its original homeostatic set-point, they  
230 cannot grow beyond the limits of their compartment unless they acquire additional mutations.  
231 Thus, if the fraction of invaded compartments is small then the original homeostatic set-point  
232 is still maintained and the fraction of invaded compartments is the same as the evolutionary  
233 stability of each compartment:  $\zeta$ .

234         What is the optimal compartment size for a population of  $N$  cells? As is the case in the  
235 somatic evolution of cancer (Michor et al., 2003) there is a tradeoff between large and small  
236 compartments. Large compartments are more robust against random drift while small  
237 compartments are more robust against mutants with a fitness advantage. To illustrate why  
238 this is the case we consider two extremes: very large and very small compartments. If the  
239 compartments are very large then, in case an invading mutant arises, it takes over a large part  
240 of the population and has a larger effect on circuit function. Very small compartments, on the  
241 other hand, are more susceptible to being taken over by mutants that are neutral or have a  
242 fitness disadvantage (Michor et al., 2003).

243

244

245

246



247 **References**

- 248 Bergman, R.N. (1989). Lilly lecture 1989. Toward physiological understanding of glucose  
249 tolerance. Minimal-model approach. *Diabetes* 38, 1512–1527.
- 250 De Gaetano, A., Hardy, T., Beck, B., Abu-Raddad, E., Palumbo, P., Bue-Valleskey, J., and  
251 Porksen, N. (2008). Mathematical models of diabetes progression. *AJP Endocrinol. Metab.*  
252 295, E1462–E1479.
- 253 Efanova, I.B., Zaitsev, S.V., Zhivotovsky, B., Köhler, M., Efendić, S., Orrenius, S., and  
254 Berggren, P.O. (1998). Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A  
255 process dependent on intracellular Ca<sup>2+</sup> concentration. *J. Biol. Chem.* 273, 33501–33507.
- 256 Ha, J., Satin, L.S., and Sherman, A.S. (2016). A Mathematical Model of the Pathogenesis,  
257 Prevention, and Reversal of Type 2 Diabetes. *Endocrinology* 157, 624–635.
- 258 Karin, O., Swisa, A., Glaser, B., Dor, Y., and Alon, U. (2016). Dynamical compensation in  
259 physiological circuits. *Mol. Syst. Biol.* 12, 886.
- 260 Maedler, K., Schumann, D.M., Schulthess, F., Oberholzer, J., Bosco, D., Berney, T., and  
261 Donath, M.Y. (2006). Aging correlates with decreased beta-cell proliferative capacity and  
262 enhanced sensitivity to apoptosis: a potential role for Fas and pancreatic duodenal homeobox-  
263 1. *Diabetes* 55, 2455–2462.
- 264 Nowak, M.A. (2006). *Evolutionary dynamics: exploring the equations of life* (Cambridge,  
265 Mass: Belknap Press of Harvard University Press).
- 266 Robinson, S.P., Langan-Fahey, S.M., Johnson, D.A., and Jordan, V.C. (1991). Metabolites,  
267 pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the  
268 breast cancer patient. *Drug Metab. Dispos. Biol. Fate Chem.* 19, 36–43.

269 Topp, B., Promislow, K., deVries, G., Miura, R.M., and Finegood, D.T. (2000). A model of  
270 beta-cell mass, insulin, and glucose kinetics: pathways to diabetes. *J. Theor. Biol.* *206*, 605–  
271 619.

272